Jeanne Menez-Jamet

This inventor holds 6 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Vaxon Biotech, Institut Pasteur, Kriptic Pharmaceuticals Limited. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeanne Menez-Jamet. Retrieved from https://idiyas.com/inventor/jeanne-menez-jamet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 7)

% Patents Active = 83.3

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 28(Granted Patents)

Company Filing History:

Kriptic Pharmaceuticals Limited

patent

4. 1 out of 1,853

National Institute of Health and Medical Research

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12728158 - Combination of Markers for Predicting the Response to Vx-001 (2026-09-08),

2. 12048737 - Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing tert (2024-07-30),

3. 10024868 - Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy (2018-07-17),

4. 8900600 - Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy (2014-12-02),

5. 8465747 - Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy (2013-06-18),

6. 8003773 - Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes (2011-08-23),

Title: Jeanne Menez-Jamet: Innovator in Cancer Immunotherapy

Introduction

Jeanne Menez-Jamet is a prominent inventor based in Montrouge, France. She has made significant contributions to the field of cancer immunotherapy, particularly through her innovative approaches to vaccine development. With a total of 6 patents, her work focuses on harnessing the immune system to target cancer cells effectively.

Latest Patents

One of her latest patents involves the use of a vaccine targeting a cryptic tert epitope for treating cancer in HLA-A*0201-positive patients with non-immunogenic tumors expressing tert. This invention pertains to a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2). This innovative approach aims to enhance the immune response against tumors. Another significant patent focuses on the identification, optimization, and use of shared HLA-B*0702 epitopes for immunotherapy. This invention provides novel methods and materials for efficiently treating patients with an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumor antigens.

Career Highlights

Throughout her career, Jeanne has worked with notable organizations such as Vaxon Biotech and Institut Pasteur. Her experience in these institutions has allowed her to develop groundbreaking technologies in cancer treatment.

Collaborations

Jeanne has collaborated with several professionals in her field, including Kostantinos (Kostas) Kosmatopoulos and Stéphanie Graff-Dubois. These collaborations have further enriched her research and contributed to her innovative work in immunotherapy.

Conclusion

Jeanne Menez-Jamet is a trailblazer in the field of cancer immunotherapy, with a focus on developing effective vaccines. Her contributions through her patents and collaborations highlight her commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.